Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3068 plus toripalimab in advanced solid tumors
NCT04721223Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-3068 in solid tumor (advanced stage), Esophageal Squamous Cell Carcinoma (ESCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), sponsored by Jacobio Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
JAB-3068
03
Conditions
solid tumor (advanced stage)Esophageal Squamous Cell Carcinoma (ESCC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04721223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721223.